Health Care • Biotechnology: Pharmaceutical Preparations
$0.56 ▼ -0.02
(-4.27%)
MKT CAP: $3.5M • VOL: 1.19M
52W L $0 52W H $187
ROARABLE / RQD
E • 30/100
PIOTROSKI
3 / 9
ONCO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $815.4K | $2.5M | $58.5K |
| YoY Revenue Growth % | -67.7% | +4217.3% | — |
| Gross Profit | $632.9K | $1.1M | — |
| Gross Margin % | 77.6% | 41.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.9M | -$56.5M | -$36.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$14.0M | -$58.7M | -$37.4M |
| EBITDA (Normalized) | — | -$56.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.7M | -$10.5M | -$13.6M |
| Capital Expenditures (CapEx) | — | $28.5K | — |
| Free Cash Flow (FCF) | -$9.7M | -$10.5M | -$13.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $15.8M | $8.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ONCO.